scholarly journals The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group

2021 ◽  
Vol 143 ◽  
pp. 127-133
Author(s):  
Archana Shenoy ◽  
Elysia Alvarez ◽  
Yueh-Yun Chi ◽  
Minjie Li ◽  
Jack F. Shern ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Oncology Group ◽  
Childhood Rhabdomyosarcoma

scholarly journals Looking up for AML in Down syndrome

Blood ◽  
2017 ◽  
Vol 129 (25) ◽  
pp. 3273-3274
Author(s):  
Jessica C. Shand
Keyword(s):  
Down Syndrome ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Prospective Trial ◽  
Prognostic Significance ◽  
Oncology Group ◽  
Reduced Intensity

In this issue of Blood, Taub et al report improved survival with reduced-intensity therapy and the prognostic significance of end-induction residual disease from the largest prospective trial to date in children with myeloid leukemia of Down syndrome (ML-DS): the Children’s Oncology Group AAML0431 study.1

scholarly journals CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group

2019 ◽  
pp. 1-15 ◽  
Author(s):  
Lata Chauhan ◽  
Miyoung Shin ◽  
Yi-Cheng Wang ◽  
Michael Loken ◽  
Jessica Pollard ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cell Surface ◽  
Clinical Response ◽  
Myeloid Leukemia ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Gemtuzumab Ozogamicin ◽  
Cell Surface Expression ◽  
Oncology Group ◽  
Acute Myeloid

PURPOSE The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic significance of CD33 splicing single nucleotide polymorphisms (SNPs), the objective of this study was to comprehensively evaluate CD33 SNPs for accurate prediction of patients with AML who are more or less likely to respond to GO. PATIENTS AND METHODS We investigated the five new CD33 SNPs (rs2455069, rs35112940, rs61736475, rs1803254, and rs201074739) for association with CD33 leukemic cell surface expression and clinical response in pediatric patients with AML enrolled in the Children’s Oncology Group AAML0531 trial. We further developed a composite CD33 pharmacogenetics (PGx) score using six CD33 SNPs (CD33_PGx6_score) for association with clinical outcome. RESULTS Four CD33 SNPs were associated with cell surface CD33 levels and clinical response in the GO versus no-GO arms. Therefore, the CD33_PGx6_score was built using directional genotype scores for the previously reported splicing SNP and five new SNPs. Patients with a CD33_PGx6_score of 0 or higher had higher CD33 expression levels compared with patients with a score of less than 0 ( P < .001). In addition, patients with a score of 0 or higher demonstrated an improved disease-free survival in the GO versus no-GO arms (62.5% ± 7.8% v 46.8% ± 8.3%, respectively; P = .008) and a reduced risk of relapse (28.3% ± 7.2% v 49.9% ± 8.4%, respectively; P < .001). No improvement from GO was observed in patients with a CD33-PGx6_score of less than 0. Consistent results were observed across the risk groups. CONCLUSION In this study, we report a composite CD33_PGx6_score using directional genotype scores of CD33 SNPs. Once validated, our findings hold promise for use of the CD33_PGx6_score to guide efficient use of GO in patients with AML. In addition, because the CD33_PGx6_score considers SNPs with varying abundance in different ethnic groups, it has potential for global application.

The calculation of actual or received dose intensity: a comparison of published methods.

1991 ◽  
Vol 9 (11) ◽  
pp. 2042-2051 ◽  
Author(s):  
D L Longo ◽  
P L Duffey ◽  
V T DeVita ◽  
M N Wesley ◽  
S M Hubbard ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Prognostic Significance ◽  
Dose Intensity ◽  
The Other ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Actual Treatment ◽  
Aggressive Histology ◽  
Impact On Treatment ◽  
Entire Treatment

Two recent reports of the same combination chemotherapy program, cyclophosphamide, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, bleomycin, and prednisone (ProMACE-CytaBOM), in similar subsets of patients with advanced-stage aggressive-histology lymphoma used two different methods to report the actual dose-intensity (DI) data. One method treats DI as a property of a particular cycle of treatment within the entire population that received that cycle. The other treats DI as a characteristic of a particular patient's entire treatment course. We have applied both methods to the same set of data and provide evidence that the latter method is preferable for at least two reasons: (1) it more accurately reflects actual DI by clearly incorporating the duration of the actual treatment course and, thus, can be used to compare the administration of same or related regimens to distinct patient populations; and (2) it allows assignment of a numerical value to an individual patient's treatment course or a group of patients' treatment courses such that DI can be examined for its impact on treatment outcome just like any other prognostic factor. The observed differences in treatment outcome between the Southwest Oncology Group (SWOG) and National Cancer Institute (NCI) studies are not clearly related to differences in distribution of clinical prognostic factors in the two study populations. The differences in methods of reporting DI prohibit evaluation of the influence of dose-related variables on outcome in the two studies. Adoption of a standard method of calculating and reporting DI data would facilitate evaluation of the prognostic significance of DI.

Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

1998 ◽  
Vol 16 (8) ◽  
pp. 2854-2863 ◽  
Author(s):  
J J Shuster ◽  
P Wacker ◽  
J Pullen ◽  
J Humbert ◽  
V J Land ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pediatric Oncology ◽  
Lymphoblastic Leukemia ◽  
Prognostic Significance ◽  
Outcome Analysis ◽  
Oncology Group ◽  
Dna Index ◽  
Duration Of Symptoms ◽  
Pediatric Oncology Group ◽  
Wbc Count

PURPOSE In childhood B-precursor acute lymphoblastic leukemia (ALL), possible interactions among sex, time, and widely used prognostic factors (age, WBC count, and DNA index) were investigated for the first 5 years after diagnosis. PATIENTS AND METHODS All eligible patients aged 1 to less than 22 years, registered between February 1986 and September 1994 in two B-precursor ALL studies from the Pediatric Oncology Group (POG), were included in the analysis. Cutpoints for age (3.0, 5.0, and 10.0 years), WBC count (10, 50, and 100 x 10(9)/L), and DNA index (DI; 1.16) were defined. Four time periods after diagnosis (years 1, 2, 3, and 4 and 5 combined) were selected for the study of prognostic significance over time. The cut-off date for analysis was April 1996. RESULTS A total of 3,717 children (2,010 boys and 1,707 girls) were included in the outcome analysis. No major differences between the sexes were observed in age, duration of symptoms before registration, WBC count, hemoglobin level, platelet count, ploidy, presence of CNS disease at diagnosis, or induction failure rate. Event-free survival (EFS) differences between sexes became significantly different from 2 years following diagnosis. At 5 years, in all subsets analyzed, boys fared worse than girls, although not all differences were statistically significant. Major sex differences in EFS were observed in older children (10 to 22 years), in patients with intermediate WBC counts (10 to 50 x 10(9)/ L), and in children who fit both of these subgroups, in whom the 2-year EFS was almost 20% higher in girls than in boys, reaching a 38% difference at 5 years. CONCLUSION This study shows an outcome interaction among sex, time, and commonly used prognostic variables. The important sex difference observed at 2 and 5 years suggests that more intensive consolidation and/or maintenance therapy in some boys with B-precursor ALL should be investigated.

scholarly journals Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: A report from the children's oncology group

2013 ◽  
Vol 134 (2) ◽  
pp. 431-436 ◽  
Author(s):  
Philip J. Lupo ◽  
Renke Zhou ◽  
Stephen X. Skapek ◽  
Douglas S. Hawkins ◽  
Logan G. Spector ◽  
...  
Keyword(s):  
Oncology Group ◽  
Related Factors ◽  
Childhood Rhabdomyosarcoma

Evaluation of early response by anatomic imaging to predict survival among patients with group III rhabdomyosarcoma: A report from the Children’s Oncology Group.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 10012-10012
Author(s):  
Douglas S. Hawkins ◽  
Abby R. Rosenberg ◽  
Elizabeth Lyden ◽  
James Robert Anderson ◽  
David A. Rodeberg ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Objective Response ◽  
Prognostic Significance ◽  
Complete Response ◽  
Early Response ◽  
Response To Therapy ◽  
Rank Test ◽  
Oncology Group ◽  
Group Iii ◽  
Kaplan Meier

10012 Background: The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging (computerized tomographic [CT] or magnetic resonance imaging [MRI] scan) is controversial. We previously reported no relationship between early response and failure-free survival (FFS) for patients on IRS-IV. We repeated the same analysis using an independent cohort of patients with non-metastatic, initially unresected RMS treated on a more recent clinical trial. Methods: A total of 338 patients enrolled in Children’s Oncology Group study D9803 met the following inclusion criteria for this analysis: 1) non-metastatic, initially unresected (Group III); 2) embryonal (ERMS) or alveolar (ARMS) histology; 3) documented response to induction chemotherapy (excluding progressive disease) based on anatomic imaging; and 4) documented therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR, complete resolution), partial response (PR, decrease of >= 50% of the sum of the products of maximum perpendicular diameters), or no response (NR, between 50% reduction and 25% increase in the sum of the products of maximum perpendicular diameters). FFS was estimated using the Kaplan-Meier method, and comparisons between groups were made using the log-rank test. Results: Overall objective response rate (CR+PR) at week 12 of therapy was 85%, with similar responses for ERMS and ARMS. FFS was similar among all patients with CR, PR, or NR (p=0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by histology (p=0.20 and p=0.45, respectively). Conclusions: These findings provide additional evidence that anatomic imaging assessment of early response to therapy among RMS patients does not predict outcome and should not be used to tailor subsequent therapy. Clinical trial information: NCT00003958. [Table: see text]

Prognostic significance of urinary neopterin in ovarian cancer a study of the Austrian Gynecologic Oncology Group.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5561-5561
Author(s):  
Christian Marth ◽  
Birgit M Volgger ◽  
Gudrun Windbichler ◽  
Alain G Zeimet ◽  
Anton Graf ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gynecologic Oncology ◽  
Prognostic Significance ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Urinary Neopterin
Sign in / Sign up

Export Citation Format

Share Document